Yotsukura, Masaya http://orcid.org/0000-0001-7012-7961
Muraoka, Yuji
Yoshida, Yukihiro
Nakagawa, Kazuo
Shiraishi, Kouya
Kohno, Takashi
Yatabe, Yasushi
Watanabe, Shun-ichi
Funding for this research was provided by:
Japan Agency for Medical Research and Development (19ck0106323h003)
Ministry of Education, Culture, Sports, Science and Technology (16KT0197, 20H00545)
Article History
Received: 26 April 2022
Accepted: 28 August 2022
First Online: 19 October 2022
Disclosure
: Yasushi Yatabe has received personal fees outside of this work from MSD, Chugai Pharmaceutical, Astra Zeneca, Pfizer Japan, Roche/Ventana, Agilent/Dako, Thermo Fisher Scientific, Archer CD, Novartis Pharma, Eli Lilly Japan, Amgen, Merck Biopharma, Sysmex, Bayer, and Daiichi Sankyo. Takashi Kohno has received personal fees outside of this work from Chugai Pharmaceutical, Eli Lilly Japan, and Sysmex Corporation.
: The study protocol was approved by the Medical Research Ethics Committee of the National Cancer Center (IRB approval no. 2015-289), and all experiments were conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the committee since our study was a retrospective review of patient records.